Author/Authors :
Mortaz، Esmaeil نويسنده Assistant to Editor-in-Chief , , Rezayat، Fatemeh نويسنده Department of Psychiatric Nursing, Tehran University of Medical Sciences, Tehran, Iran; , , Amani ، Davar نويسنده Department of Immunology, School of Medicine , , Kiani، Arda نويسنده Tracheal Disease Research Center,NRITLD, Shahid Beheshti University M.C., TEHRAN-IRAN. , , Garssen، Johan نويسنده Division of Pharmacology and Pathophysiology Utrecht Institute for Pharmaceutical Sciences, Faculty of Sciences, Utrecht University, Utrecht, The Netherlands. Garssen, Johan , Adcock، Ian M. نويسنده Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK Adcock, Ian M. , Velayati، Aliakbar نويسنده Clinical Tuberculosis and Epidemiology Research Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran ,
Abstract :
Sarcoidosis is a systemic granulomatous disorder of unidentified etiology, with a heterogeneous clinical presentation. It is characterized by a reduced delayed-type hypersensitivity to tuberculin and common antigens. The balance between Th1, Th17 and Regulatory T(Treg) cells controls T-cell proliferation and activation.The Th17/Treg ratio in the peripheral blood and bronchoalveolar lavage fluidis increased in patients with active sarcoidosis. Amplified IL-17A expression in granulomas and the presence of IL-17A+, IL-17A+IL-4+ and IL-17A+IFN-γ+ memory T helper cells in the circulation and BAL indicate Th17 cell involvement in granuloma induction and/or maintenance in sarcoidosis. Sarcoidosis should therefore be considered as a Th1/Th17 multisystem disorder and anti-IL-17/Th17 approaches that control and reduce IL-17Amay be an option, therefore, for the treatment of sarcoidosis.Here we provide a short overview as to the role of Th17 cells as critical cells in the pathogenesis of sarcoidosis.
